- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Zydus Lifesciences Limited — Updates, 13-01-2026: Press Release
13-01-2026 | 10:01 am
13-01-2026 | 10:01 am
Zydus Lifesciences' subsidiary, Sentynl Therapeutics, received FDA approval for ZYCUBO® to treat Menkes disease. This first-of-its-kind therapy offers significant survival benefits for pediatric patients, marking a key business development and opening a new market.
No comments yet. Be the first to comment!